LBCTR2021064778尚未招募2 期
Escalating Dose and Randomized, Controlled Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 2
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 0 至 10（—）
- 性别
- All
入选标准
- •Part A, B and C:
- •- Genetic documentation of 5q SMA (homozygous gene deletion, mutation, or compound heterozygote)
- •- Onset of clinical signs and symptoms consistent with SMA at > 6 months (> 180 days) of age (i.e., later-onset SMA)
- •- Age 2 to = 15 years, inclusive, at the time of informed consent
- •- Participants with SMA symptom onset = 6 months (= 180 days) of age (infantile onset) should have age > 1 week to = 7 months (= 210 days) at the time of informed consent
- •- Participants with SMA symptom onset > 6 months (> 180 days) of age (later onset):
- •*Age 2 to < 10 years at the time of informed consent
- •*Can sit independently but has never had the ability to walk independently
- •*HFMSE score = 10 and = 54 at Screening
- •- Participants = 18 years of age at Screening must be ambulatory
- •- Currently on nusinersen treatment at the time of Screening, with the first dose being at least 1 year prior to Screening
排除标准
- •Part A, B and C:
- •- Presence of an untreated or inadequately treated active infection requiring systemic antiviral or antimicrobial therapy at any time during the Screening period
- •- Presence of an implanted shunt for the drainage of cerebrospinal fluid (CSF) or of an implanted central nervous system (CNS) catheter
- •- Hospitalization for surgery, pulmonary event, or nutritional support within 2 months prior to Screening or planned within 12 months after the participant's first dose.
- •- Respiratory insufficiency, defined by the medical necessity for invasive or noninvasive ventilation for > 6 hours during a 24-hour period, at Screening
- •- Medical necessity for a gastric feeding tube
- •- Treatment with an investigational drug given for the treatment of SMA, biological agent, or device within 30 days or 5 half-lives of the agent, whichever is longer, prior to Screening or anytime during the study; any prior or current treatment with any survival motor neuron-2 (SMN2)-splicing modifier or gene therapy; or prior antisense oligonucleotide treatment, or cell transplantation.
- •- Treatment with an investigational drug given for the treatment of SMA, biological agent, or device within 30 days or 5 half-lives of the agent, whichever is longer, prior to Screening or anytime during the study; any prior or current treatment with any SMN2-splicing modifier or gene therapy; or prior antisense oligonucleotide treatment, or cell transplantation
- •- Participants with SMA symptom onset > 6 months (> 180 days) of age (later onset):
- •*Respiratory insufficiency, defined by the medical necessity for invasive or noninvasive ventilation for > 6 hours during a 24-hour period, at Screening
- •*Medical necessity for a gastric feeding tube
- •*Participants with SMA symptom onset = 6 months (= 180 days) of age (infantile-onset): Signs or symptoms of SMA present at birth or within the first week after birth.
- •- Concurrent or previous participation and/or administration of nusinersen in another clinical study
- •NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
研究者
相似试验
进行中（未招募）
1 期
Study of Nusinersen (BIIB058) in Participants With Spinal Muscular AtrophyMuscular Atrophy, SpinalMedDRA version: 20.1Level: PTClassification code 10041582Term: Spinal muscular atrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2019-002663-10-HUBiogen Idec Research Limited100
进行中（未招募）
1 期
Study of Nusinersen (BIIB058) in Participants With Spinal Muscular AtrophyMuscular Atrophy, SpinalMedDRA version: 20.1Level: PTClassification code 10041582Term: Spinal muscular atrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2019-002663-10-NLBiogen Idec Research Limited172
进行中（未招募）
1 期
Study of Nusinersen (BIIB058) in Participants With Spinal Muscular AtrophyMuscular Atrophy, SpinalMedDRA version: 20.1Level: PTClassification code 10041582Term: Spinal muscular atrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2019-002663-10-FRBiogen Idec Research Limited152
进行中（未招募）
1 期
Study of Nusinersen (BIIB058) in Participants With Spinal Muscular AtrophyMuscular Atrophy, SpinalMedDRA version: 20.1Level: PTClassification code 10041582Term: Spinal muscular atrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2019-002663-10-ITBIOGEN IDEC RESEARCH LIMITED152
进行中（未招募）
1 期
Study of Nusinersen (BIIB058) in Participants With Spinal Muscular AtrophyMuscular Atrophy, SpinalMedDRA version: 20.1Level: PTClassification code 10041582Term: Spinal muscular atrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2019-002663-10-LVBiogen Idec Research Limited100